Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
12
MDNA.TO Quote, Financials, Valuation and Earnings
Last price:
$0.94
Seasonality move
:
-1.47%
Day range:
$0.93 - $0.99
52-week range:
$0.78 - $1.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.66x
Volume:
70.1K
Avg. volume:
146K
1-year change:
-49.73%
Market cap:
$78.4M
Revenue:
--
EPS (TTM):
-$0.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDNA.TO
Medicenna Therapeutics Corp.
|
-- | -- | -- | -- | $3.88 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
ZEN.V
Zentek Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDNA.TO
Medicenna Therapeutics Corp.
|
$0.94 | $3.88 | $78.4M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
|
ZEN.V
Zentek Ltd.
|
$1.00 | -- | $107.3M | -- | $0.00 | 0% | 114.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDNA.TO
Medicenna Therapeutics Corp.
|
1.43% | -0.349 | 0.18% | 3.53x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
|
ZEN.V
Zentek Ltd.
|
13.91% | -0.347 | 1.7% | 0.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDNA.TO
Medicenna Therapeutics Corp.
|
-$23K | -$5.5M | -83.92% | -84.77% | -- | -$4.9M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
|
ZEN.V
Zentek Ltd.
|
-$1.2M | -$2.4M | -50.39% | -54.49% | -38887.1% | -$1.5M |
Medicenna Therapeutics Corp. vs. Competitors
-
Which has Higher Returns MDNA.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Medicenna Therapeutics Corp.'s net margin of --. Medicenna Therapeutics Corp.'s return on equity of -84.77% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDNA.TOMedicenna Therapeutics Corp.-- -$0.06 $10.4M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About MDNA.TO or COOL.CX?
Medicenna Therapeutics Corp. has a consensus price target of $3.88, signalling upside risk potential of 312.23%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicenna Therapeutics Corp. has higher upside potential than Core One Labs, Inc., analysts believe Medicenna Therapeutics Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDNA.TOMedicenna Therapeutics Corp.4 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is MDNA.TO or COOL.CX More Risky?
Medicenna Therapeutics Corp. has a beta of 1.821, which suggesting that the stock is 82.118% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock MDNA.TO or COOL.CX?
Medicenna Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicenna Therapeutics Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDNA.TO or COOL.CX?
Medicenna Therapeutics Corp. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Medicenna Therapeutics Corp.'s net income of -$4.9M is higher than Core One Labs, Inc.'s net income of --. Notably, Medicenna Therapeutics Corp.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicenna Therapeutics Corp. is -- versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDNA.TOMedicenna Therapeutics Corp.-- -- -- -$4.9M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns MDNA.TO or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Medicenna Therapeutics Corp.'s net margin of --. Medicenna Therapeutics Corp.'s return on equity of -84.77% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDNA.TOMedicenna Therapeutics Corp.-- -$0.06 $10.4M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About MDNA.TO or CURE.X.CX?
Medicenna Therapeutics Corp. has a consensus price target of $3.88, signalling upside risk potential of 312.23%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicenna Therapeutics Corp. has higher upside potential than Biocure Technology, analysts believe Medicenna Therapeutics Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings MDNA.TOMedicenna Therapeutics Corp.4 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is MDNA.TO or CURE.X.CX More Risky?
Medicenna Therapeutics Corp. has a beta of 1.821, which suggesting that the stock is 82.118% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDNA.TO or CURE.X.CX?
Medicenna Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicenna Therapeutics Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDNA.TO or CURE.X.CX?
Medicenna Therapeutics Corp. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Medicenna Therapeutics Corp.'s net income of -$4.9M is higher than Biocure Technology's net income of --. Notably, Medicenna Therapeutics Corp.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicenna Therapeutics Corp. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDNA.TOMedicenna Therapeutics Corp.-- -- -- -$4.9M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns MDNA.TO or HEAL.CX?
has a net margin of -- compared to Medicenna Therapeutics Corp.'s net margin of --. Medicenna Therapeutics Corp.'s return on equity of -84.77% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDNA.TOMedicenna Therapeutics Corp.-- -$0.06 $10.4M HEAL.CX-- -- -- -
What do Analysts Say About MDNA.TO or HEAL.CX?
Medicenna Therapeutics Corp. has a consensus price target of $3.88, signalling upside risk potential of 312.23%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicenna Therapeutics Corp. has higher upside potential than , analysts believe Medicenna Therapeutics Corp. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings MDNA.TOMedicenna Therapeutics Corp.4 0 0 HEAL.CX0 0 0 -
Is MDNA.TO or HEAL.CX More Risky?
Medicenna Therapeutics Corp. has a beta of 1.821, which suggesting that the stock is 82.118% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDNA.TO or HEAL.CX?
Medicenna Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicenna Therapeutics Corp. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDNA.TO or HEAL.CX?
Medicenna Therapeutics Corp. quarterly revenues are --, which are larger than quarterly revenues of --. Medicenna Therapeutics Corp.'s net income of -$4.9M is higher than 's net income of --. Notably, Medicenna Therapeutics Corp.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicenna Therapeutics Corp. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDNA.TOMedicenna Therapeutics Corp.-- -- -- -$4.9M HEAL.CX-- -- -- --
-
Which has Higher Returns MDNA.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Medicenna Therapeutics Corp.'s net margin of --. Medicenna Therapeutics Corp.'s return on equity of -84.77% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MDNA.TOMedicenna Therapeutics Corp.-- -$0.06 $10.4M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About MDNA.TO or NSHS.CX?
Medicenna Therapeutics Corp. has a consensus price target of $3.88, signalling upside risk potential of 312.23%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicenna Therapeutics Corp. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Medicenna Therapeutics Corp. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDNA.TOMedicenna Therapeutics Corp.4 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is MDNA.TO or NSHS.CX More Risky?
Medicenna Therapeutics Corp. has a beta of 1.821, which suggesting that the stock is 82.118% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock MDNA.TO or NSHS.CX?
Medicenna Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicenna Therapeutics Corp. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDNA.TO or NSHS.CX?
Medicenna Therapeutics Corp. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Medicenna Therapeutics Corp.'s net income of -$4.9M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Medicenna Therapeutics Corp.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicenna Therapeutics Corp. is -- versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDNA.TOMedicenna Therapeutics Corp.-- -- -- -$4.9M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
-
Which has Higher Returns MDNA.TO or ZEN.V?
Zentek Ltd. has a net margin of -- compared to Medicenna Therapeutics Corp.'s net margin of -38567.74%. Medicenna Therapeutics Corp.'s return on equity of -84.77% beat Zentek Ltd.'s return on equity of -54.49%.
Company Gross Margin Earnings Per Share Invested Capital MDNA.TOMedicenna Therapeutics Corp.-- -$0.06 $10.4M ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M -
What do Analysts Say About MDNA.TO or ZEN.V?
Medicenna Therapeutics Corp. has a consensus price target of $3.88, signalling upside risk potential of 312.23%. On the other hand Zentek Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Medicenna Therapeutics Corp. has higher upside potential than Zentek Ltd., analysts believe Medicenna Therapeutics Corp. is more attractive than Zentek Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MDNA.TOMedicenna Therapeutics Corp.4 0 0 ZEN.VZentek Ltd.0 0 0 -
Is MDNA.TO or ZEN.V More Risky?
Medicenna Therapeutics Corp. has a beta of 1.821, which suggesting that the stock is 82.118% more volatile than S&P 500. In comparison Zentek Ltd. has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.176%.
-
Which is a Better Dividend Stock MDNA.TO or ZEN.V?
Medicenna Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zentek Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medicenna Therapeutics Corp. pays -- of its earnings as a dividend. Zentek Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDNA.TO or ZEN.V?
Medicenna Therapeutics Corp. quarterly revenues are --, which are smaller than Zentek Ltd. quarterly revenues of $6.2K. Medicenna Therapeutics Corp.'s net income of -$4.9M is lower than Zentek Ltd.'s net income of -$2.4M. Notably, Medicenna Therapeutics Corp.'s price-to-earnings ratio is -- while Zentek Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medicenna Therapeutics Corp. is -- versus 114.11x for Zentek Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDNA.TOMedicenna Therapeutics Corp.-- -- -- -$4.9M ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
